GlassScriptPhysician profile
Taylor Sue Eves
NPI 1225428063
$12,234.07
in general payments reported to CMS, 2019-2025
33 companies · $736 in 2025
The $736 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,827 · 2022: $2,707 · 2023: $3,179 · 2024: $2,786 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,464 · Education: $236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,464.24 |
| Education | $235.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,252.70 | 2021-2024 | |
| Janssen Biotech, INC. | $1,245.62 | 2021-2025 | Tremfya |
| Lilly USA, LLC | $1,227.02 | 2021-2025 | Taltz, Olumiant, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $1,054.31 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $971.96 | 2021-2024 | Ilumya, Odomzo, Blu-U |
| Pfizer INC. | $846.63 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $736.07 | 2021-2025 | Dupixent, Libtayo |
| Amgen INC. | $668.45 | 2021-2024 | Otezla |
| Ucb, INC. | $654.13 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $572.82 | 2021-2025 | |
| Leo Pharma INC. | $323.38 | 2021-2025 | Adbry |
| Dermavant Sciences, INC. | $299.93 | 2022-2024 | Vtama |
| Genzyme Corporation | $255.93 | 2021-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $179.10 | 2021-2024 | Siliq |
| Mayne Pharma Commercial LLC | $174.67 | 2021-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $149.41 | 2023-2024 | Zoryve |
| Incyte Corporation | $139.75 | 2021-2024 | Opzelura |
| Genentech USA, INC. | $104.05 | 2021-2023 | Erivedge |
| Galderma Laboratories, L.P. | $59.14 | 2021-2023 | |
| Kyowa Kirin, INC. | $46.38 | 2022-2023 | Poteligeo |
| Organon LLC | $45.74 | 2025 | Vtama, Nexplanon |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.32 | 2023 | Spevigo |
| Insulet Corporation | $31.44 | 2024 | Omnipod |
| Vyne Pharmaceuticals INC. | $23.52 | 2021 | |
| Dexcom, INC. | $20.12 | 2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $17.85 | 2024 | Freestyle Libre 3 |
| Boston Scientific Corporation | $17.25 | 2023 | Watchman Flx |
| Helsinn Therapeutics (U.S.), INC. | $15.72 | 2021 | |
| Biogen, INC. | $14.49 | 2025 | Skyclarys |
| Paratek Pharmaceuticals, INC. | $13.97 | 2021 | |
| Dermira, INC. | $13.11 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.47 | 2021 | |
| Phathom Pharmaceuticals, INC. | $3.62 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Eves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.